Premixed insulin ups hypoglycemia in inpatients

Premixed insulin ups hypoglycemia in inpatients

(HealthDay)—For hospitalized patients with diabetes, treatment with premixed insulin results in similar glycemic control but higher frequency of hypoglycemia compared with a basal-bolus regimen, according to a study published online Oct. 12 in Diabetes Care.

Virginia Bellido, from Hospital Universitario Central de Asturias in Spain, and colleagues conducted a prospective, open-label trial in which inpatients with diabetes were randomized to receive a basal-bolus regimen with glargine once daily and glulisine before meals (33 patients) or premixed human insulin twice daily (30 percent regular insulin, 70 percent NPH insulin; 39 patients).

The study was stopped prematurely at the first prespecified interim analysis because of an increased frequency of hypoglycemia >50 percent in patients treated with premixed human insulin. The researchers found that 64 and 24 percent of patients treated with premixed insulin and a basal-bolus regimen, respectively, experienced one or more episodes of hypoglycemia (P < 0.001). After the first day of , there were no differences seen in mean daily between the groups. In 55.9 percent of blood glucose readings in the basal-bolus group and 54.3 percent in the premixed insulin group, a target between 80 and 180 mg/dL before meals was achieved (P = 0.23).

"Inpatient treatment with premixed human insulin resulted in similar glycemic control but in significantly higher frequency of hypoglycemia compared with treatment with basal-bolus regimen in hospitalized with diabetes," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Sanofi-Aventis, which funded the study.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Diabetes Care

Copyright © 2015 HealthDay. All rights reserved.

Citation: Premixed insulin ups hypoglycemia in inpatients (2015, October 16) retrieved 29 February 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Long-acting analog insulin doesn't up AMI risk in T2DM


Feedback to editors